Carregant...

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

INTRODUCTION: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic respo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2899790/
https://ncbi.nlm.nih.gov/pubmed/20694077
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!